Navigation Links
Aderans Research Acquires Intercytex Assets
Date:3/25/2010

(Atlanta, GA, March 24, 2010) Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company.

Atlanta, GA (PRWeb UK) March 25, 2010 -- Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company. The acquisition represents a significant consolidation within the hair regeneration industry, as ARI is absorbing the scientific assets of a company that was its leading competitor.

“This acquisition is a major step forward for ARI,” said Vern Liebmann, Vice President, Operations. “Through this deal, we’ve been able to consolidate the majority of key patents and know-how in the hair regeneration field, an achievement that can accelerate our ability to deliver a commercially viable product to market. This acquisition was only possible thanks to the considerable financial support of Aderans Holdings Company, Ltd., of Japan.”

The purchase includes assets related to the ICX-TRC product that Regenerative Medicine Assets Limited had been developing. ICX-TRC is an autologous hair regeneration therapy for the treatment of male pattern baldness and female diffuse alopecia.

The deal comes as ARI is expanding its Phase 2 clinical study of cell-based hair regeneration, in which it recently treated the trial’s 100th subject. “We’ve acquired important proprietary knowledge that includes Intercytex’s clinical efforts to date,” noted Ken Washenik, MD PhD, Executive Vice President. “This information should substantially augment our ongoing efforts to produce a cell-based treatment for hair loss.”

“Cellular regeneration represents the leading edge of research into hair loss,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “Combining the knowledge stores of two of the leading companies in this field is a major step forward in our efforts to pioneer a process of cellular hair regeneration that can deliver enhanced hair growth to millions of people around the world.”

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Holdings Company, Ltd., the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html

Additional information on ARI can be found at www.aderansresearch.com.

Learn more about Aderans Holdings Company, Ltd. at http://www.aderans.co.jp/e/company/

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3774184.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Aderans Research Treats One-Hundredth Subject in Clinical Study
2. Researchers Identify 2 Genes Linked to Fatty Liver Disease
3. NIA researchers find gene to explain mouse embryonic stem cell immortality
4. Researchers discover fundamental step in immune-system development
5. Sino Veda Herbal Product Maker Goes Natural in Edmonton Research Park
6. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
7. BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now
8. Childrens Mental Health Conference Brings Together Top Research, Professionals, Parents and Community Agencies, April 8-9 in Miami
9. Innovative Service Revolutionizes How Businesses Research Product Sales Potential
10. MAYO Communications Retained by MAMMOJAM 2010 Dr. Susan Love Research Foundation Event
11. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aderans Research Acquires Intercytex Assets 
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn ... business channels. , While many results are clear, much of PR is hard to ... When it comes to measurement, firms should always take an all-inclusive approach that takes ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... restoration treatment, is proud to announce a new blog post about women’s hair loss. ... women suffer from hair loss as they age. Menopause or genetics can be two ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... New patients ... Braasch for leading sleep apnea treatment, with or without a referral. Sleep apnea is ... which can include daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch ...
(Date:3/27/2017)... ... , ... New patients who want to experience the benefits of dental ... placed by Dr. Manju Kejriwal, with or without a referral. Dr. Kejriwal is a ... of each dental implant placement. The i-CAT CBCT system captures the shapes of oral ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Medtec Europe ... more than 600 exhibitors from 70 countries the ... solutions that will advance the medical technology industry. ... the Messe Stuttgart, Stuttgart, Germany ... platform showcasing the key trends and insights across ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
Breaking Medicine Technology: